Dr. Kamyar Hadian is a principal investigator and the head of the ‘Assay Development and Screening Platform’ at the Helmholtz Zentrum Muenchen in Munich/Germany, and in 2016, he also became an adjunct associate research scientist in the Department of Biological Sciences at the Columbia University, New York (US). His research focus is the identification and validation of novel molecular targets within ubiquitin signalling pathways and the subsequent development of strategies to interfere with these targets. He has in-depth experience in designing and running biochemical as well as cell-based assays for high-throughput and high-content screening in various disease areas such as cancer, immunology, virology, diabetes and more. Kamyar studied Biology at the Technical University of Munich (TUM) and received his PhD from the Ludwig-Maximilians-University (LMU) in 2009 for his studies in HIV research, where he elucidated virus-host interactions. After a short post-doctoral period working in the field of NF-κB signalling, he was appointed the head of ‘Assay Development and Screening Platform’ at the Helmholtz Zentrum Muenchen in 2010. Five years later (in 2015), he received a tenure position.